CA2389667A1 - Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors - Google Patents

Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors Download PDF

Info

Publication number
CA2389667A1
CA2389667A1 CA002389667A CA2389667A CA2389667A1 CA 2389667 A1 CA2389667 A1 CA 2389667A1 CA 002389667 A CA002389667 A CA 002389667A CA 2389667 A CA2389667 A CA 2389667A CA 2389667 A1 CA2389667 A1 CA 2389667A1
Authority
CA
Canada
Prior art keywords
cells
vector
cell
molecule
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389667A
Other languages
English (en)
French (fr)
Inventor
Teresa Occhiodoro
Patrick Salmon
Didier Trono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Geneva
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389667A1 publication Critical patent/CA2389667A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002389667A 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors Abandoned CA2389667A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99123498.0 1999-11-25
EP99123498A EP1103615A1 (en) 1999-11-25 1999-11-25 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
PCT/EP2000/011723 WO2001038548A2 (en) 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors

Publications (1)

Publication Number Publication Date
CA2389667A1 true CA2389667A1 (en) 2001-05-31

Family

ID=8239461

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389667A Abandoned CA2389667A1 (en) 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors

Country Status (6)

Country Link
US (1) US20090142841A1 (enExample)
EP (2) EP1103615A1 (enExample)
JP (1) JP2003514565A (enExample)
AU (1) AU2667901A (enExample)
CA (1) CA2389667A1 (enExample)
WO (1) WO2001038548A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
CA2680613A1 (en) 2007-03-13 2008-09-18 National Jewish Medical And Research Center Methods for generation of antibodies
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
DK2313496T3 (en) * 2008-07-21 2014-12-15 Taiga Biotechnologies Inc Anukleære differentiated cells, and method for preparation thereof
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
EP2501801A1 (en) 2009-11-18 2012-09-26 The Board of Trustees of The Leland Stanford Junior University Methods of inducing tissue regeneration
JP5863338B2 (ja) * 2011-08-25 2016-02-16 株式会社東芝 プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
ES2634457T3 (es) 2011-10-18 2017-09-27 Univercell Biosolutions Producción de una línea de células beta humanas a partir de un páncreas postnatal temprano
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CN103468746B (zh) * 2013-09-28 2015-03-04 青岛麦迪赛斯生物科技有限公司 一种肿瘤细胞系的构建方法
CA3024296A1 (en) 2016-05-11 2017-11-16 Animal Cell Therapy - Act Production of a canine beta cell line from an immature pancreas
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
EP3707243A1 (en) 2017-11-08 2020-09-16 Animal Cell Therapy - Act Production of canine pancreatic islets from an immature pancreas
EP3952909A4 (en) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
SG11202112529WA (en) 2019-05-14 2021-12-30 Taiga Biotechnologies Inc Compositions and methods for treating t cell exhaustion
CN111154807B (zh) * 2020-01-17 2023-03-24 山东农业大学 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法
WO2022066937A1 (en) * 2020-09-23 2022-03-31 Regents Of The University Of Minnesota Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use
US20230407268A1 (en) * 2020-11-06 2023-12-21 Trans Chromosomics, Inc. Method for producing reversibly immortalized cell
KR102572595B1 (ko) * 2020-12-02 2023-08-31 충북대학교 산학협력단 불멸화 고양이줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
KR102456805B1 (ko) * 2020-12-02 2022-10-24 충북대학교 산학협력단 불멸화 개줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
CN112941033A (zh) * 2021-03-11 2021-06-11 深圳市人民医院 永生化饲养层细胞株的构建方法、永生化饲养层细胞株及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686306A (en) * 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US5919997A (en) * 1993-11-18 1999-07-06 Cold Spring Habor Labortary Transgenic mice having modified cell-cycle regulation
US5729597A (en) * 1995-05-16 1998-03-17 At&T Corp Service and information management system for a telecommunications network
US5629159A (en) * 1995-06-07 1997-05-13 California Institute Of Technology Immortalization and disimmortalization of cells
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2319238T3 (es) * 1996-07-01 2009-05-05 Gemin X Pharmaceuticals Canada Inc. Composiciones para modular la longitud de los talomeros.
CA2265522A1 (en) * 1996-09-17 1998-03-26 The Salk Institute For Biological Studies Retroviral vectors capable of transducing non-dividing cells
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
ATE298371T1 (de) * 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
AU759437B2 (en) * 1998-01-12 2003-04-17 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
ES2291025T3 (es) * 1998-05-13 2008-02-16 Genetix Pharmaceuticals Inc. Celulas lentivirales de empaquetamiento.

Also Published As

Publication number Publication date
JP2003514565A (ja) 2003-04-22
EP1244798A2 (en) 2002-10-02
WO2001038548A2 (en) 2001-05-31
AU2667901A (en) 2001-06-04
EP1103615A1 (en) 2001-05-30
WO2001038548A3 (en) 2001-10-18
US20090142841A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
US20090142841A1 (en) Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
Reiser et al. Development of multigene and regulated lentivirus vectors
US8652837B2 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
Salmon et al. Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes
KR102091957B1 (ko) 레트로바이러스 생산을 위한 안정한 세포주
Hamaguchi et al. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro
Boris-Lawrie et al. Recent advances in retrovirus vector technology
CA2328404C (en) Novel lentiviral packaging cells
US5830725A (en) Rapid, stable high-titre production of recombing retrovirus
US20220315950A1 (en) Bio-production of lentiviral vectors
KR20000049250A (ko) 렌티바이러스 벡터
EP4144856A1 (en) Production cell and packaging cell for retroviral vector and preparation method therefor
Sparacio et al. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors
CN110520535B (zh) 用于逆转录病毒产生的稳定细胞系
Mikkola et al. Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells
US20080124308A1 (en) Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins
Gropp et al. Lentiviral vector–mediated gene delivery into human embryonic stem cells
Painter et al. Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post‐therapeutic deletion of tumorigenesis
Molina et al. Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector
Trono et al. Hanna Mikkola, Niels-Bjarne Woods, Marketa Sjögren
Tomás et al. LentiPro26
US20060134137A1 (en) Transduction vector based on modified HIV-2
Kafri Gene Delivery by Lentivirus Vectors
Hennig et al. HEK293-based production platform for γ-retroviral (SIN-) vectors: application for safe and efficient transfer of COL7A1 cDNA
Curran et al. Recombinant feline immunodeficiency virus vectors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued